In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please cancel claims 8 and 22, amend claims 6, 9, and 12, and add new claims 25-34 as follows.

- 1-5. (canceled).
- 6. (currently amended) A process of preparing a pyrene actin composition comprising:
 - a) concentrating a pyrene actin composition; and
- b) mixing the concentrated pyrene actin composition with sucrose, a stabilizing agent, and a reducing agent, thereby generating a second pyrene actin composition; and
 - c) rapidly freezing the second pyrene actin composition.
- 7-8. (canceled).
- (currently amended) The process of elaim 8 claim 6, further comprising:
 d) Ivophilizing the frozen second pyrene actin composition generated in step c.
- (previously presented) The process of claim 6 wherein said reducing agent is dithiothreitol.
- 11. (previously presented) The process of claim 10, wherein the concentration of dithiothreitol is 10 mM.
- (currently amended) The process of elaim-8 claim 6, wherein the second pyrene actin composition is rapidly frozen in liquid nitrogen or a dry ice ethanol bath.
- 13. (previously presented) The process of claim 6, wherein said stabilizing agent is dextran.

2

DOCKET NO.: 133071,00401

PATENT

- 14. (previously presented) The process of claim 9, wherein the frozen second pyrene actin composition is lyophilized for 40 hours over a temperature from -40°C to 30°C.
- (previously presented) The process of claim 6, wherein said pyrene actin is concentrated to 0.2 to 40 mg/ml.
- (previously presented) The process of claim 6, wherein said pyrene actin is concentrated to greater than 10 mg/ml.
- (previously presented) The process of claim 6 wherein said pyrene actin composition of step a) comprises ATP and CaCl₂.
- 18. (previously presented) The process of claim 6 wherein said sucrose is present in the second pyrene actin composition in amount of 5% w/v.
- 19. (previously presented) The process of claim 6 wherein said stabilizing agent is present in the second pyrene actin composition in an amount of 1% w/v.
- 20. (previously presented) The process of claim 9 further comprising:
- e) resuspending the lyophilized and frozen second pyrene actin composition in a buffer comprising 5 mM Tris pH 8, 0.2 mM CaCl₂, and 0.2 mM ATP, thereby generating a resuspended pyrene actin composition; and
 - f) incubating said resuspended pyrene actin composition on ice.
- (previously presented) The method of claim 20 wherein said resuspended pyrene actin composition is centrifuged.
- 22-24. (cancelled).

3

- 25. (new) A process of preparing a pyrene actin composition comprising:
 - a) concentrating a pyrene actin composition:
- b) mixing the concentrated pyrene actin composition with stabilizing agents and a reducing agent, thereby generating a second pyrene actin composition;
 - c) rapidly freezing the second pyrene actin composition; and
 - d) lyophilizing the frozen second pyrene actin composition generated in step c.
- 26. (new) The process of claim 25 wherein said reducing agent is dithiothreitol.
- 27. (new) The process of claim 25 wherein said stabilizing agents are dextran and sucrose.
- 28. (new) The process of claim 25 further comprising:
- e) resuspending the lyophilized and frozen second pyrene actin composition in a buffer comprising 5 mM Tris pH 8, 0.2 mM CaCl₂, and 0.2 mM ATP, thereby generating a resuspended pyrene actin composition; and
 - f) incubating said resuspended pyrene actin composition on ice.
- 29. (new) A method for producing a stabilized form of pyrene actin comprising:

concentrating pyrene actin to greater than 10 mg/ml and mixing with a reducing agent, and sucrose and dextran stabilizing agents to produce a concentrated pyrene actin;

rapidly freezing the concentrated pyrene actin to produce a frozen concentrated pyrene actin; and

lyophilizing the frozen concentrated pyrene actin with a gradient temperature profile from -40°C to +30°C to produce the stabilized form of pyrene actin, wherein the stabilized form of pyrene actin retains its ability to polymerize with the typical nucleation for more than 3 years when stored at 4°C.

30. (new) The process of claim 29 wherein the concentration of sucrose is 5% and the concentration of dextran is 1%

DOCKET NO.: 133071.00401 PATENT

31. (new) The process of claim 29 wherein the concentration of pyrene actin prior to freezing is greater than 20 mg/ml.

- 32. (new) The process of claim 29 wherein the reducing agent is dithiothreitol.
- 33. (new) The process of claim 29 wherein the lyophilized and frozen concentrated pyrene actin is rehydrated with 5 mM Tris-HCl, 0.2 mM adenosine triphosphate, 0.2 mM CaCl₂ and 10 mM dithiothreitol to create a solution of pyrene actin.
- 34. (new) The method of claim 33 whereby the solution of pyrene actin is polymerized by adding 50 mM KCl, 2 mM MgCl₂ and 1 mM adenosine triphosphate.

5